Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies

News provided by

Oct 08, 2013, 07:49 ET

NEW YORK, Oct. 8, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies
http://www.reportlinker.com/p01661964/Solid-Tumors-Market-in-Asia-Pacific-to-2019---New-Drug-Approvals-and-Anticipated-Product-Launches-to-Trigger-a-Shift-in-Treatment-Paradigm-to-Targeted-Therapies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies", which provides in-depth analysis of four key therapeutic indications within the Asia-Pacific (APAC) solid tumors market – bladder cancer, ovarian cancer, pancreatic cancer and prostate cancer – covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these four solid tumor types.

The value of the solid tumors market in the APAC region amounted to an estimated $1 billion in 2012 and is expected to register a modest Compound Annual Growth Rate (CAGR) of 12.3% to reach $2.3 billion in 2019. The key drivers for growth in this market include: new product approvals in ovarian, pancreatic and prostate cancers; expected launches from the promising ovarian and prostate cancer pipelines; and increased market penetration due to the anticipated implementation of social insurance in China. Conversely, the growth of the market in this region could face some restricting influences, including: the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; low access and penetration; and price erosion due to generic competition.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the bladder cancer, ovarian cancer, pancreatic cancer and prostate cancer in the four APAC markets of Australia, China, India and Japan. The report includes -
- Disease overview, as well as treatment algorithms and treatment usage patterns
- Market size and forecast for the APAC solid tumors market from 2012 to 2019
- Major marketed products in the APAC region for all four solid tumor types covered
- In-depth pipeline analysis for all four solid tumor types
- Key drivers and restraints that have had and are expected to have a significant impact upon the market
- Key licensing and co-development agreements in the solid tumors market

Reasons to buy

The report will enhance your decision-making capability by allowing you to -
- Align your product portfolio to the markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the solid tumors market
- Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10
2 Solid Tumors Market in Asia Pacific to 2019 - Introduction 11
2.1 Introduction 11
3 Solid Tumors Market in Asia Pacific to 2019 - Therapeutic Landscape 12
3.1 Bladder Cancer 12
3.1.1 Symptoms 12
3.1.2 Etiology 12
3.1.3 Pathophysiology 12
3.1.4 Diagnosis 12
3.1.5 Classification 13
3.1.6 Epidemiology 14
3.1.7 Prognosis and Disease Staging 15
3.1.8 Treatment Options 17
3.2 Ovarian Cancer 22
3.2.1 Symptoms 22
3.2.2 Etiology 22
3.2.3 Pathophysiology 23
3.2.4 Diagnosis 23
3.2.5 Classification 25
3.2.6 Epidemiology 25
3.2.7 Prognosis and Disease Staging 26
3.2.8 Treatment Options 28
3.3 Pancreatic Cancer 31
3.3.1 Symptoms 31
3.3.2 Etiology 31
3.3.3 Pathophysiology 32
3.3.4 Diagnosis 32
3.3.5 Classification 32
3.3.6 Epidemiology 32
3.3.7 Prognosis and Disease Staging 34
3.3.8 Treatment Algorithm 36
3.4 Prostate Cancer 37
3.4.1 Symptoms 37
3.4.2 Etiology 37
3.4.3 Pathophysiology 37
3.4.4 Co-Morbidities and Complications 38
3.4.5 Diagnosis 38
3.4.6 Classification 39
3.4.7 Epidemiology 39
3.4.8 Prognosis and Disease Staging 41
3.4.9 Treatment Options 43
4 Solid Tumors Market in Asia Pacific to 2019 - Marketed Products 45
4.1 Bladder Cancer 45
4.2 Ovarian Cancer 45
4.3 Pancreatic Cancer 46
4.4 Prostate Cancer 47
4.5 Key Marketed Products 47
4.5.1 Carboplatin 47
4.5.2 Cisplatin 48
4.5.3 Gemcitabine 48
4.5.4 Paclitaxel 49
4.5.5 Doxorubicin 49
4.5.6 Avastin (bevacizumab) 50
4.5.7 Tarceva (erlotinib) 51
4.5.8 Sutent (sunitinib) 52
4.5.9 Afinitor (everolimus) 53
4.5.10 Taxotere (docetaxel) 54
4.5.11 Zytiga (abiraterone acetate) 54
4.5.12 Jevtana (cabazitaxel) 56
5 Solid Tumors Market in Asia Pacific to 2019 - Pipeline Analysis 57
5.1 Bladder Cancer Pipeline 57
5.1.1 Overall Pipeline 57
5.1.2 Pipeline Analysis by Molecule Type 58
5.1.3 Pipeline Analysis by Mechanism of Action 59
5.2 Ovarian Cancer Pipeline 60
5.2.1 Overall Pipeline 60
5.2.2 Pipeline Analysis by Molecule Type 62
5.2.3 Pipeline Analysis by Mechanism of Action 63
5.3 Pancreatic Cancer Pipeline 64
5.3.1 Overall Pipeline 64
5.3.2 Pipeline Analysis by Molecule Type 65
5.3.3 Pipeline Analysis by Mechanism of Action 66
5.4 Prostate Cancer Pipeline 67
5.4.1 Overall Pipeline 67
5.4.2 Pipeline Analysis by Molecule Type 68
5.4.3 Pipeline Analysis by Mechanism of Action 69
5.5 Promising Drug Candidates in the Pipeline 70
5.5.1 Abraxane (albumin-bound paclitaxel) 70
5.5.2 AMG 386 (trebananib) 70
5.5.3 Votrient (pazopanib) 71
5.5.4 Xtandi (enzalutamide) 72
6 Solid Tumors Market in Asia Pacific to 2019- Market Forecast 73
6.1 Asia-Pacific Market 73
6.1.1 Treatment Usage Patterns 73
6.1.2 Annual Cost of Treatment 73
6.1.3 Market Size 73
6.2 India 75
6.2.1 Treatment Usage Patterns 75
6.2.2 Annual Cost of Treatment 75
6.2.3 Market Size 75
6.3 Australia 77
6.3.1 Treatment Usage Patterns 77
6.3.2 Annual Cost of Treatment 77
6.3.3 Market Size 78
6.4 China 80
6.4.1 Treatment Usage Patterns 80
6.4.2 Annual Cost of Treatment 80
6.4.3 Market Size 80
6.5 Japan 82
6.5.1 Treatment Usage Patterns 82
6.5.2 Annual Cost of Treatment 82
6.5.3 Market Size 82
6.6 Drivers and Barriers for the Solid Tumors Market in APAC 84
6.6.1 Drivers 84
6.6.2 Barriers 84
7 Solid Tumors Market in Asia Pacific to 2019 - Deals and Strategic Consolidations 86
7.1 Deals Analysis 86
7.2 Major Co-Development Deals 87
7.2.1 ScinoPharm Taiwan and Coland Enter into Agreement to Develop Generic Oncological Drugs 88
7.2.2 Bind Biosciences Enters into Agreement with Amgen to Develop Cancer Drugs 88
7.2.3 Merck Enters into Co-Development Agreement with Endocyte for Cancer Drug 88
7.2.4 Merck Serono Enters into Co-Development Agreement with Threshold Pharma for TH-302, Pancreatic Cancer Drug 89
7.2.5 Seattle Genetics Exercises Option for Co-Development Agreement with Agensys (affiliate of Astellas) for ASG-15ME 89
7.3 Major Licensing Deals 90
7.3.1 Spectrum Pharma Amends Licensing Agreement with Allergan for Apaziquone 91
7.3.2 Chugai Pharma Enters Into Licensing Agreement with Debiopharm Group for FF284 91
7.3.3 Baxter International Enters into Licensing Agreement with Onconova Therapeutics for Rigosertib 91
7.3.4 Dyax Enters Into Licensing Agreement with Kadmon for Oncology Drug 91
7.3.5 Medigene Extends Licensing Agreement with Syncore for EndoTAG-1 92
8 Solid Tumors Market in Asia Pacific to 2019 - Appendix 93
8.1 Pipeline Drugs by Phase 93
8.1.1 Phase III 93
8.1.2 Pre-registration/NDA-filed 94
8.2 Market Forecasts to 2018 95
8.2.1 APAC 95
8.2.2 Australia 96
8.2.3 China 98
8.2.4 India 99
8.2.5 Japan 101
8.3 Market Definitions 102
8.4 Abbreviations 102
8.5 Sources 104
8.6 Research Methodology 107
8.6.1 Coverage 107
8.6.2 Secondary Research 107
8.6.3 Primary Research 108
8.6.4 Therapeutic Landscape 108
8.6.5 Geographical Landscape 110
8.6.6 Pipeline Analysis 111
8.7 Expert Panel Validation 111
8.8 Contact Us 111
8.9 Disclaimer 111

1.1 List of Tables

Table 1: Solid Tumors Market, Bladder Cancer, AJCC TNM Staging System, 2010 16
Table 2: Solid Tumors Market, Bladder Cancer, Treatment by Staging, 2013 21
Table 3: Solid Tumors Market, Ovarian Cancer, AJCC's TNM and FIGO Staging Systems, 2013 27
Table 4: Solid Tumors Market, Pancreatic Cancer, AJCC TNM Staging System, 2013 35
Table 5: Solid Tumors Market, Prostate Cancer, AJCC Staging System, 2013 42
Table 6: Solid Tumors Market, Global, Pharmaceutical Pipeline (Phase III), 2013 93
Table 7: Solid Tumors Market, Global, Pharmaceutical Pipeline (Pre-registration/NDA-filed), 2013 94
Table 8: Solid Tumors Market, Asia-Pacific, Ovarian Cancer, Market Forecast, 2012–2019 95
Table 9: Solid Tumors Market, Asia-Pacific, Bladder Cancer, Market Forecast, 2012–2019 95
Table 10: Solid Tumors Market, Asia-Pacific, Pancreatic Cancer, Market Forecast, 2012–2019 95
Table 11: Solid Tumors Market, Asia-Pacific, Prostate Cancer, Market Forecast, 2012–2019 96
Table 12: Solid Tumors Market, Australia, Ovarian Cancer, Market Forecast, 2012–2019 96
Table 13: Solid Tumors Market, Australia, Bladder Cancer, Market Forecast, 2012–2019 96
Table 14: Solid Tumors Market, Australia, Pancreatic Cancer, Market Forecast, 2012–2019 97
Table 15: Solid Tumors Market, Australia, Prostate Cancer, Market Forecast, 2012–2019 97
Table 16: Solid Tumors Market, China, Ovarian Cancer, Market Forecast, 2012–2019 98
Table 17: Solid Tumors Market, China, Bladder Cancer, Market Forecast, 2012–2019 98
Table 18: Solid Tumors Market, China, Pancreatic Cancer, Market Forecast, 2012–2019 99
Table 19: Solid Tumors Market, China, Prostate Cancer, Market Forecast, 2012–2019 99
Table 20: Solid Tumors Market, India, Ovarian Cancer, Market Forecast, 2012–2019 99
Table 21: Solid Tumors Market, India, Bladder Cancer, Market Forecast, 2012–2019 100
Table 22: Solid Tumors Market, India, Pancreatic Cancer, Market Forecast, 2012–2019 100
Table 23: Solid Tumors Market, India, Prostate Cancer, Market Forecast, 2012–2019 100
Table 24: Solid Tumors Market, Japan, Ovarian Cancer, Market Forecast, 2012–2019 101
Table 25: Solid Tumors Market, Japan, Bladder Cancer, Market Forecast, 2012–2019 101
Table 26: Solid Tumors Market, Japan, Pancreatic Cancer, Market Forecast, 2012–2019 101
Table 27: Solid Tumors Market, Japan, Prostate Cancer, Market Forecast, 2012–2019 102

1.2 List of Figures

Figure 1: Solid Tumors Market, Asia-Pacific, Bladder Cancer, Epidemiology, 2012–2019 14
Figure 2: Solid Tumors Market, Bladder Cancer, Treatment Algorithm, Superficial and Stage I, 2013 19
Figure 3: Solid Tumors Market, Bladder Cancer, Treatment Algorithm, Stage II and III, 2013 19
Figure 4: Solid Tumors Market, Asia-Pacific, Ovarian Cancer, Epidemiology, 2012–2019 26
Figure 5: Solid Tumors Market, Ovarian Cancer, Treatment Algorithm, Stage I and II, 2013 29
Figure 6: Solid Tumors Market, Ovarian Cancer, Treatment Algorithm, Stage III and IV, 2013 30
Figure 7: Solid Tumors Market, Asia-Pacific, Pancreatic Cancer, Epidemiology, 2012–2019 33
Figure 8: Solid Tumors Market, Pancreatic Cancer, Treatment Algorithm, 2013 36
Figure 9: Solid Tumors Market, Asia-Pacific, Prostate Cancer, Epidemiology, 2012–2019 40
Figure 10: Solid Tumors Market, Prostate Cancer, Treatment Algorithm, 2013 44
Figure 11: Solid Tumors Market, Global, Avastin, Annual Sales ($m), 2006–2013e 50
Figure 12: Solid Tumors Market, Global, Tarceva, Annual Sales ($m), 2006–2013e 51
Figure 13: Solid Tumors Market, Global, Sutent, Annual Sales ($m), 2006–2013e 52
Figure 14: Solid Tumors Market, Global, Afinitor, Annual Sales ($m), 2009–2013e 53
Figure 15: Solid Tumors Market, Global, Zytiga, Annual Sales ($m), 2011–2013e 55
Figure 16: Solid Tumors Market, Global, Jevtana, Annual Sales ($m), 2010–2013e 56
Figure 17: Solid Tumors Market, Global, Bladder Cancer, Pipeline, 2013 57
Figure 18: Solid Tumors Market, Global, Bladder Cancer, Pipeline by Molecule Type, 2013 58
Figure 19: Solid Tumors Market, Global, Bladder Cancer, Pipeline by Mechanism of Action, 2013 59
Figure 20: Solid Tumors Market, Global, Ovarian Cancer, Pipeline, 2013 61
Figure 21: Solid Tumors Market, Global, Ovarian Cancer, Pipeline by Molecule Type, 2013 62
Figure 22: Solid Tumors Market, Global, Ovarian Cancer, Pipeline by Mechanism of Action, 2013 63
Figure 23: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline, 2013 64
Figure 24: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline by Molecule Type, 2013 65
Figure 25: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline by Mechanism of Action, 2013 66
Figure 26: Solid Tumors Market, Global, Prostate Cancer, Pipeline, 2013 67
Figure 27: Solid Tumors Market, Global, Prostate Cancer, Pipeline by Molecule Type, 2013 68
Figure 28: Solid Tumors Market, Global, Prostate Cancer, Pipeline by Mechanism of Action, 2013 69
Figure 29: Solid Tumors Market, Asia-Pacific, Market Size ($m), 2012–2019 74
Figure 30: Solid Tumors Market, India, Market Size ($m), 2012–2019 76
Figure 31: Solid Tumors Market, Australia, Market Size ($m), 2012–2019 79
Figure 32: Solid Tumors Market, China, Market Size ($m), 2012–2019 81
Figure 33: Solid Tumors Market, Japan, Market Size ($m), 2012–2019 83
Figure 34: Solid Tumors Market, Global, Deals, 2006–2013 86
Figure 35: Solid Tumors Market, Global, Co-development Deals, 2006–2013 87
Figure 36: Solid Tumors Market, Global, Licensing Deals, 2006-2013 90
Figure 37: GBI Research Market Forecasting Model 110